Drug Eluting Coronary Stent System
- UID
- IMP/MD/2019/000457_6a11d97158630de4cf3efb410f3c818b_b1b7c0baf7df0b573ec67df0be31c4bb
- Device class
- Class D
- Brand name
- BioFreedom
- License holder
- Cartier Healthcare LLP
- Approving authority
- CDSCO
- Product information
- The BioMatrix NeoFlex DES is indicated for improving coronary luminal diameter for the treatment of de novo lesions in native coronary arteries with a reference diameter ranging between 2.25 mm and 4.0 mm. Stents with length 33 mm and 36 mm are only available for artery diameters ranging between 2.5 mm and 3.5 mm. The BioMatrix NeoFlex DES with stent length up to 28 mm is also indicated for use in patients with: • ST elevated myocardial infarction (BioFreedom) • Acute Coronary Syndromes (BioFreedom) including ACS-STEMI, ACS-NSTEMI and Unstable Angina • Diabetes Mellitus
Drug Eluting Coronary Stent System is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/MD/2019/000457_6a11d97158630de4cf3efb410f3c818b_b1b7c0baf7df0b573ec67df0be31c4bb. This device is marketed under the brand name BioFreedom. The license holder is Cartier Healthcare LLP, and it is classified as Device Class Class D. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.